Glenmark Pharmaceuticals share price
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,300.00up ₹34.30 (1.51%)BSE ₹2,300.35
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,265.70.
28 Oct: open ₹2,268.00, high ₹2,318.00, low ₹2,261.90
52-week range of traded prices to 28 Oct 2026
₹1,792.60Low, 28 Oct 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,912 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.10
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.35
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,55,83040.2% delivered
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, based in Mumbai, develops, makes and sells branded and generic medicines, specialty medicines and over-the-counter products, with a focus on respiratory, dermatology and oncology (cancer) treatments.123 It sells to healthcare professionals, hospitals, government wholesalers, distributors and pharmacies in India, North America, Europe and emerging markets.14
It reports one business segment, pharmaceuticals, and runs it as a base business, an innovation and specialty business, and Ichnos Glenmark Innovation (IGI), a subsidiary that develops cancer antibodies on its own BEAT platform.567 Its consumer brands in India, such as Candid, Scalpe and La Shield, sit in Glenmark Consumer Care Limited, a wholly owned subsidiary.89 It has 11 manufacturing sites, 4 of them approved by the US FDA, and 6 R&D centres, in Sinnar, Taloja, Mahape, Lausanne, New York and Neuchâtel.1011 Its products are exported to more than 80 countries, and it has subsidiaries in North America, Europe, Latin America, Asia-Pacific, the Middle East, Australia and Africa.1112
It was incorporated in 1977, founded by Gracias Saldanha, and listed its shares on NSE and BSE in 2000.1314 In 2019 it spun out its active pharmaceutical ingredients business (the chemicals that make a medicine work), now Alivus Life Sciences, and in 2024 it sold its 75% stake in that company to Nirma Limited.1516 The Saldanha Family Trust, a promoter, held 45.45% of the shares at the end of March 2026; Glenn Saldanha, also a promoter, is Chairman and Managing Director.1718
Glenmark Pharmaceuticals key points
Results
- In the quarter to Jun 2026, consolidated revenue rose 23.1% to ₹40,185 million. EBITDA (profit before interest, tax, depreciation and amortisation) was ₹8,048 million, a 20.03% margin, and profit after tax ₹4,828 million, an 11.8% margin.19
- In the year to Mar 2026, consolidated revenue from operations was ₹169,825 million, up 27.5% from ₹133,217 million.20
- EBITDA that year rose to ₹45,724 million from ₹23,514 million, a 26.9% margin helped by income from licensing ISB 2001, and profit after tax was ₹13,620 million.21
- It had no debt and a net cash position (cash and investments above borrowings) of ₹11,763 million at the end of March 2026.2223
Market position
- In India it ranked 13th with a 2.37% market share as of June 2026. It ranked 2nd in dermatology, 3rd in respiratory and 4th in cardiac medicines.24
Where revenue comes from
- Revenue by region, ₹ million252627North America includes deferred ISB 2001 licensing income; without it, the region grew 19.8%.
Item quarter to Jun 2026 quarter to Jun 2025 India 14,321 12,399 North America 10,974 7,780 Europe 7,472 6,678 Emerging markets 7,304 5,721 - India formulation sales fell 17.0% to ₹37,237 million in the year to Mar 2026, from ₹44,845 million, after a one-time hit that followed the GST change announced in August 2025.28
- North America revenue rose to ₹71,390 million from ₹30,172 million in the year to Mar 2026, including income from licensing ISB 2001; the underlying business was broadly stable.29
Specialty and partnered brands
- Ryaltris, its own nasal spray for allergic rhinitis (hay fever), was sold in 57 markets as of June 2026, with applications in more than 90 countries; its secondary sales grew upwards of 40% a year.3031
- Tevimbra and Brukinsa, cancer medicines sold in India with BeOne Medicines since the quarter to Jun 2025, earned over ₹100 crore in their first 12 months.3233
- As of June 2026 it had filed for approval of partnered cancer medicines aumolertinib, from Hansoh, in 13 countries and envafolimab in 24 countries.3435
Research and development
- R&D spending was about ₹10,000 million in the year to Mar 2026, with 964 R&D staff, and it held more than 1,360 patents in March 2026.3637
- In July 2025, its subsidiary IGI licensed ISB 2001, an antibody in trials for multiple myeloma (a blood cancer), to AbbVie for North America, Europe, Japan and Greater China; Glenmark keeps the rights in emerging markets.38
- IGI received $700 million upfront in September 2025 and can earn up to $1.225 billion in milestones, plus tiered double-digit royalties on sales.39
What the company expects
- On its earnings call of 3 Aug 2026, the company said it expects an overall margin of 21% to 22% for the year to Mar 2027.40
- On its earnings call of 3 Aug 2026, the company said 12% to 15% growth could be assumed for its India business on a consistent basis from here on.41
- On its earnings call of 3 Aug 2026, the company said branded products in Europe were around 30% of total revenues and should reach about 60% in 5 years; it expected high single-digit European growth in the year to Mar 2027.42
- On its earnings call of 3 Aug 2026, the company said it expects at least 2 or 3 more US respiratory launches, and aumolertinib's first launch, in the half year to Mar 2027.4234
Recent events
- On 23 Sep 2026, it announced receiving the US FDA's report on the June 2026 inspection of its Goa plant, with Voluntary Action Indicated status (issues noted, no regulatory action required).43
- On 10 Sep 2026, India Ratings upgraded its long-term bank loan rating to IND AA+ from IND AA, with a stable outlook.44
- On 4 Mar 2026, it announced US FDA approval of its generic of the FloVent HFA 44 mcg inhaler, with 180 days of exclusivity once sold.45
- On 27 Nov 2025, it announced a US FDA inspection report with Voluntary Action Indicated status for its Monroe plant in the US, earlier under a warning letter (a formal notice of violations) from June 2023; manufacturing would restart.46
Litigation and regulatory matters
- Its US subsidiary and 76 co-defendants face lawsuits alleging generic drug price-fixing. It agreed to settle with direct purchasers for $37.75 million and state attorneys general for $29.628 million, subject to court approval, admitting no liability; on 3 Aug 2026 other plaintiff groups remained.474849
- In August 2023 its US subsidiary resolved a criminal price-fixing charge over pravastatin under a deferred prosecution agreement (charges dropped if terms are met): $30 million in 6 instalments, 3 paid by Mar 2026, and it stops distributing pravastatin in the US.50
- On 11 Aug 2026, it agreed to settle Humana's claims in the generic drug price-fixing litigation for $15.28 million, already provided for in its accounts.5147
Last updated
All 51 sources, each with its page
- 1. Annual report, 13 Aug 2026, page 269
- 2. Annual report, 13 Aug 2026, page 193
- 3. Annual report, 13 Aug 2026, page 3
- 4. Annual report, 13 Aug 2026, page 33
- 5. Annual report, 13 Aug 2026, page 451
- 6. Annual report, 13 Aug 2026, page 119
- 7. Annual report, 13 Aug 2026, page 260
- 8. Annual report, 13 Aug 2026, page 194
- 9. Annual report, 13 Aug 2026, page 192
- 10. Annual report, 13 Aug 2026, page 107
- 11. Annual report, 13 Aug 2026, page 269
- 12. Annual report, 13 Aug 2026, page 203
- 13. Annual report, 13 Aug 2026, page 261
- 14. Annual report, 13 Aug 2026, page 24
- 15. Annual report, 13 Aug 2026, page 24
- 16. Annual report, 13 Aug 2026, page 25
- 17. Annual report, 13 Aug 2026, page 431
- 18. Annual report, 13 Aug 2026, page 35
- 19. Investor presentation, 31 Jul 2026, page 4
- 20. Annual report, 13 Aug 2026, page 192
- 21. Annual report, 13 Aug 2026, page 101
- 22. Annual report, 13 Aug 2026, page 101
- 23. Annual report, 13 Aug 2026, page 103
- 24. Earnings call, 3 Aug 2026, page 2
- 25. Investor presentation, 31 Jul 2026, page 5
- 26. Investor presentation, 31 Jul 2026, page 7
- 27. Earnings call, 3 Aug 2026, page 3
- 28. Annual report, 13 Aug 2026, page 193
- 29. Annual report, 13 Aug 2026, page 194
- 30. Earnings call, 3 Aug 2026, page 4
- 31. Annual report, 13 Aug 2026, page 33
- 32. Annual report, 13 Aug 2026, page 194
- 33. Earnings call, 3 Aug 2026, page 9
- 34. Earnings call, 3 Aug 2026, page 5
- 35. Earnings call, 3 Aug 2026, page 4
- 36. Annual report, 13 Aug 2026, page 98
- 37. Annual report, 13 Aug 2026, page 99
- 38. Annual report, 13 Aug 2026, page 197
- 39. Annual report, 13 Aug 2026, page 197
- 40. Earnings call, 3 Aug 2026, page 8
- 41. Earnings call, 3 Aug 2026, page 9
- 42. Earnings call, 3 Aug 2026, page 7
- 43. Exchange filing, 23 Sep 2026, page 2
- 44. Exchange filing, 11 Sep 2026, page 2
- 45. Exchange filing, 4 Mar 2026, page 2
- 46. Exchange filing, 27 Nov 2025, page 1
- 47. Annual report, 13 Aug 2026, page 449
- 48. Annual report, 13 Aug 2026, page 195
- 49. Earnings call, 3 Aug 2026, page 13
- 50. Annual report, 13 Aug 2026, page 449
- 51. Exchange filing, 11 Aug 2026, page 1
Results
Consolidated; ₹ crore.Glenmark Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +32.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +138.4%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹4,018 Crup 6.57%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹483 Crup 60.24%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.0%
Revenue by quarter
Peak revenue ₹6,047 Cr, quarter to Sep 2025; lowest ₹3,256 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Net profit | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| Net margin | 10.3% | 10.3% | 0.1% | 1.4% | 10.1% | 10.3% | 8.0% | 12.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹16,983 Crup 27.48%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,362 Crup 30.06%
- Net margin
- 8.0%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2024, the company's revenue for that year, ₹11,813 Cr, differs from its quarters added, ₹12,179 Cr; the company reports a discontinued business.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9,186 | 9,103 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 11,813 | 13,322 | 16,983 |
| Net profit | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | −1,434 | 1,047 | 1,362 |
| Net margin | 12.1% | 8.8% | 9.4% | 7.3% | 8.9% | 8.1% | 2.9% | – | 7.9% | 8.0% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2024: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2024: days before it are of the company before the change.Glenmark Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 33% of 247 trading days over the last year.
LowestHighest
Its median17.89Industry median28.10
Price to book
At or below today's level on 91% of 1,971 trading days since Nov 2018.
LowestHighest
Its median2.36Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 0.1% of 2,440 trading days over the last 10 years.
LowestHighest
Its median0.34%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +38.6% | +30.0% | +6.4% | 0.2% |
| 3 years | +66.4% | +66.1% | 0.0% | 0.2% |
| 5 years | +36.0% | +7.0% | +26.7% | 0.4% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2025 and Mar 2026.
Mutual fund holdings
235 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 124 of the 151 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 4 more funds filed their first portfolio on record, holding it.All 235 funds holding Glenmark Pharmaceuticals
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 68
- CutCut. Funds that held fewer shares than at the end of the month before.
- 83
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 74
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 11
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 1,34,08,183 | 3.07% | ₹3,130.4 Cr |
 Invesco India Mid Cap FundInvesco Mutual Fund | 18,64,031 | 2.76% | ₹435.2 Cr |
| Invesco India Contra FundInvesco Mutual Fund | 17,01,870 | 2.06% | ₹397.3 Cr |
| Invesco India Large & Mid Cap FundInvesco Mutual Fund | 13,42,939 | 2.57% | ₹313.5 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 11,63,093 | 1.31% | ₹271.5 Cr |
 ICICI Prudential Arbitrage FundICICI Prudential Mutual Fund | 10,54,500 | 0.69% | ₹246.2 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 10,48,046 | 0.86% | ₹244.7 Cr |
 SBI Arbitrage FundSBI Mutual Fund | 9,58,875 | 0.48% | ₹223.9 Cr |
 Kotak Arbitrage FundKotak Mahindra Mutual Fund | 9,55,125 | 0.30% | ₹223.0 Cr |
| Bandhan Small Cap FundBandhan Mutual Fund | 9,22,877 | 0.60% | ₹215.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Glenmark Pharmaceuticals insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
- Others: no market trade · 1 pledge filing of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Glenmark Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Glenmark Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 CiplaCIPLA | 1,10,323 | 38.08 | 3.12 | −0.7% | −46.8% | 8.5% | 9.7% | 0.95% |
 Mankind PharmaMANKIND | 1,02,848 | 45.74 | 5.85 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 94,638 | 25.49 | 2.50 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 90,210 | 16.32 | 4.02 | +28.2% | +49.5% | 27.9% | 28.2% | 0.91% |
 Alkem LaboratoriesALKEM | 60,619 | 28.10 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.05% |
 BioconBIOCON | 57,153 | 115.39 | 1.68 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Abbott IndiaABBOTINDIA | 55,833 | 34.58 | 11.69 | +6.3% | +11.2% | 35.9% | 39.6% | 2.50% |
 Gland PharmaGLAND | 50,312 | 44.57 | 4.86 | +17.6% | +46.5% | 11.6% | 12.4% | 0.66% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Glenmark Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹5.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 31 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹2.50 |
| 3 Oct 2025 | Interim | ₹2.50 |
| 15 Sep 2025 | Final | ₹2.50 |
| 13 Sep 2024 | Final | ₹2.50 |
| 18 Sep 2023 | Final | ₹2.50 |
| 12 Sep 2022 | Final | ₹2.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Glenmark Pharmaceuticals announcements
Oct 2026
23 Oct · Analysts
23 Oct · Board meeting
Sep 2026
21 Sep · Analysts
Glenmark Pharmaceuticals share price by year
Each calendar year to 2025.Glenmark Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,035.20 | +26.5% | 2,226.70 | 1,278.95 |
| 2024 | 1,609.10 | +88.4% | 1,818.15 | 797.20 |
| 2023 | 853.95 | +101.3% | 865.40 | 371.15 |
| 2022 | 424.15 | −19.8% | 525.25 | 352.45 |
| 2021 | 528.55 | +7.1% | 687.05 | 443.95 |
| 2020 | 493.50 | +42.0% | 535.50 | 188.10 |
| 2019 | 347.45 | −49.9% | 692.15 | 274.80 |
| 2018 | 693.05 | +16.5% | 696.75 | 500.60 |
| 2017 | 594.75 | −33.1% | 959.35 | 532.15 |
| 2016 | 888.45 | −3.6% | 965.25 | 691.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 2,214.70 | 2,275.00 | 2,214.60 | 2,265.70 | 2,252.19 | 4,83,378 | 42.3% |
| 26 Oct 2026 | 2,135.60 | 2,229.00 | 2,133.00 | 2,225.80 | 2,195.84 | 9,69,672 | 51.5% |
| 23 Oct 2026 | 2,196.00 | 2,203.80 | 2,101.60 | 2,166.60 | 2,134.72 | 8,92,797 | 52.3% |
| 22 Oct 2026 | 2,168.00 | 2,218.80 | 2,160.30 | 2,198.50 | 2,195.90 | 5,76,619 | 55.3% |
| 21 Oct 2026 | 2,216.00 | 2,249.80 | 2,163.10 | 2,194.10 | 2,194.59 | 5,68,717 | 49.3% |
| 19 Oct 2026 | 2,230.10 | 2,269.90 | 2,200.00 | 2,210.20 | 2,227.91 | 2,85,702 | 42.3% |
| 16 Oct 2026 | 2,250.50 | 2,266.90 | 2,223.70 | 2,226.70 | 2,243.79 | 6,95,427 | 63.0% |
| 15 Oct 2026 | 2,242.00 | 2,289.50 | 2,241.20 | 2,250.50 | 2,264.34 | 4,88,525 | 49.6% |
| 14 Oct 2026 | 2,275.00 | 2,286.40 | 2,242.00 | 2,246.00 | 2,257.09 | 2,57,936 | 44.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 22 Jun 2020 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 12 Mar 2020 | Price move | – | Between two trading sessions the price moved by a fifth or more. The Nifty 500 moved 5% or more the same way over the same sessions. Not adjusted for. |
| 28 Jan 2009 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company's board met on results that day or since the trading day before. Not adjusted for. |
| 10 Sep 2007 | Split | 0.5000 | Each share became 2. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- GLENMARK
- BSE code
- 532296
- ISIN
- INE935A01035
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.glenmarkpharma.com
- CIN
- L24299MH1977PLC019982
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1977
- Registered office
- B2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400026, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, Nifty Midcap 100